New DNA booster shot targets omicron variants
NCT ID NCT06436911
First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 16 times
Summary
This study tested a new booster vaccine called Covigenix VAX-002 in 46 healthy adults aged 18 and older. The vaccine uses DNA technology to target newer Omicron variants of the virus that causes COVID-19. The goal was to check if the booster is safe and helps the body build a strong immune response. All participants had already received a prior COVID-19 vaccine or had a recent infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID - 19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centricity Research
Burlington, Ontario, L7M4Y1, Canada
-
Centricity Research
Toronto, Ontario, M4G3E8, Canada
-
Centricity Research
Toronto, Ontario, M9W4L6, Canada
-
Diex Recherche
Sherbrooke, Quebec, J1L0H8, Canada
-
Diex Recherche Quebec
Québec, Quebec, G1V4T3, Canada
-
University of Alberta
Edmonton, Alberta, Canada
Conditions
Explore the condition pages connected to this study.